IPHAInnate PharmaFinished
IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Lymphoma, T-Cell · Lymphoma, T-Cell, Cutaneous · Mycosis Fungoides/Sezary Syndrome
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 170 (final count)
- Started
- May 22, 2019
- Main results expected
- Jan 8, 2026
- Fully finished
- Jan 8, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR)
Measured over: From the first dose until study completion, an expected average of 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03902184 · record last updated 2026-04-29 · checked 2026-11-09 15:42 UTC